Alterity Therapeutics Limited
ATHE
NASDAQ·Healthcare·Biotechnology·Mkt cap $76.9M
$4.54
▲ +0.44%
P/E
—
Mkt Cap
$76.9M
52-Wk Range
$2.66–$5.89
52-Week Range
$2.66 - $5.89
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 12.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.0).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Strong
+15.8% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying ATHE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 28, 2026
Reported EPS of -$0.05 vs -$0.12 consensus (+56.0% surprise). Revenue of $289.0K vs $2.3M expected (-87.5%).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+56.0%
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Craig-Hallum · Aug 11, 2026
vs Industry
How ATHE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.